DANA Inc
DAN · Motor Vehicle Parts & Accessories · 108.2M shares · -0%/yr ↓ buyback · EDGAR filings ↗
Net buyback after stock comp: $637M (gross $650M, SBC $13M)
Reference price $22.48 · est. market cap ~$2.4B — last insider sale, 2025-11-25 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C62Mid-pack auto-parts supplier with thin margins and sub-1x interest coverage, mid-cycle restructuring.
Strengths
- ROE 10.1% (60.6th pct) and improving net income growth; $469M cash (79.3rd pct) plus $2.66B Off-Highway divestiture proceeds to cut debt
- Cost program (~$325M savings) and $2B buyback authorization
Risks
- Razor-thin margins (gross 8%/21.9th pct, operating 1.85%/34.5th, net 1.1%) and interest coverage of just 0.77x
- Heavy customer concentration (top 10 = 76% of sales) and cyclical EV-adoption exposure
Notable findings
- No interest coverageInterest coverage 0.77 (cannot cover interest)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Customer concentration~76% of revenue from one customer/distributor — Sales to our ten largest customers accounted for 76% of our overall sales in 2025
- Strong balance sheetStrong balance sheet — $469M cash & investments
- Trial readout soonUpcoming trial readout ~2026-05 — PHASE2 · Breast Cancer Radiation
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
8.0%
Operating margin
1.9%
Net margin
1.1%
Return on equity
10.1%
Return on assets
1.1%
Revenue growth (QoQ)
0.1%
Interest coverage
0.8×
Current ratio
1.2×
Tangible book value
$769M
Cash & investments
$469M
Stock comp / revenue
0.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-14 | Kellett James D | Tax withheld | 768 | $33.16 |
| 2026-02-14 | Foster Byron S. | Option exercise | 14K | — |
| 2026-02-14 | Foster Byron S. | Option exercise | 1.2K | — |
| 2026-02-14 | Foster Byron S. | Tax withheld | 6.5K | $33.16 |
| 2026-02-14 | Liedberg Douglas H | Option exercise | 11K | — |
| 2026-02-14 | Liedberg Douglas H | Tax withheld | 5.2K | $33.16 |
| 2026-02-14 | Liedberg Douglas H | Option exercise | 939 | — |
| 2026-02-14 | Kraus Timothy R | Option exercise | 18K | — |
| 2026-02-14 | Kraus Timothy R | Option exercise | 1.6K | — |
| 2026-02-14 | Kraus Timothy R | Tax withheld | 8.4K | $33.16 |
| 2026-02-14 | Kellett James D | Option exercise | 2.4K | — |
| 2026-02-14 | Kellett James D | Option exercise | 213 | — |
| 2026-02-13 | Kellett James D | Option exercise | 191 | — |
| 2026-02-13 | Kellett James D | Tax withheld | 1.1K | $33.16 |
| 2026-02-13 | Foster Byron S. | Option exercise | 20K | — |
| 2026-02-13 | Foster Byron S. | Option exercise | 1.1K | — |
| 2026-02-13 | Liedberg Douglas H | Option exercise | 17K | — |
| 2026-02-13 | Liedberg Douglas H | Option exercise | 960 | — |
| 2026-02-13 | Liedberg Douglas H | Tax withheld | 7.9K | $33.16 |
| 2026-02-13 | Kraus Timothy R | Option exercise | 30K | — |
| 2026-02-13 | Kraus Timothy R | Option exercise | 1.7K | — |
| 2026-02-13 | Foster Byron S. | Tax withheld | 9.1K | $33.16 |
| 2026-02-13 | Kraus Timothy R | Tax withheld | 14K | $33.16 |
| 2026-02-13 | Kellett James D | Option exercise | 3.4K | — |
| 2026-02-11 | LaFreniere Nora E. | Option exercise | 10K | — |
| 2026-02-11 | Karlin Bridget E | Option exercise | 10K | — |
| 2026-02-11 | Karlin Bridget E | Option exercise | 227 | — |
| 2026-02-11 | Hernandez Ernesto M | Option exercise | 10K | — |
| 2026-02-11 | Hernandez Ernesto M | Option exercise | 227 | — |
| 2026-02-11 | Hernandez Ernesto M | Tax withheld | 3.1K | $32.07 |
| 2026-02-11 | LaFreniere Nora E. | Option exercise | 227 | — |
| 2026-02-11 | Pour Brian Keith | Option exercise | 15K | — |
| 2026-02-11 | Pour Brian Keith | Option exercise | 330 | — |
| 2026-02-11 | Pour Brian Keith | Tax withheld | 6.7K | $32.07 |
| 2026-02-11 | Liedberg Douglas H | Option exercise | 14K | — |
| 2026-02-11 | Liedberg Douglas H | Option exercise | 311 | — |
| 2026-02-11 | Liedberg Douglas H | Tax withheld | 6.4K | $32.07 |
| 2026-02-11 | Kraus Timothy R | Option exercise | 27K | — |
| 2026-02-11 | Kraus Timothy R | Option exercise | 611 | — |
| 2026-02-11 | Kraus Timothy R | Tax withheld | 12K | $32.07 |
| 2026-02-11 | Kellett James D | Option exercise | 2.8K | — |
| 2026-02-11 | Kellett James D | Option exercise | 60 | — |
| 2026-02-11 | Kellett James D | Tax withheld | 995 | $32.07 |
| 2026-02-11 | Foster Byron S. | Option exercise | 21K | — |
| 2026-02-11 | Foster Byron S. | Option exercise | 465 | — |
| 2026-02-11 | Foster Byron S. | Tax withheld | 9.2K | $32.07 |
| 2026-02-11 | WANDELL KEITH E | Option exercise | 10K | — |
| 2026-02-11 | WANDELL KEITH E | Option exercise | 227 | — |
| 2026-02-11 | OConnell Diarmuid B. | Option exercise | 10K | — |
| 2026-02-11 | OConnell Diarmuid B. | Option exercise | 227 | — |
| 2026-02-11 | Nelligan Hanna Olivia | Option exercise | 2.6K | — |
| 2026-02-11 | Nelligan Hanna Olivia | Option exercise | 11 | — |
| 2026-02-11 | Mack Michael J | Option exercise | 10K | — |
| 2026-02-11 | Mack Michael J | Option exercise | 227 | — |
| 2026-02-06 | Kraus Timothy R | Grant | 92K | $30.40 |
| 2026-02-06 | Kraus Timothy R | Option exercise | 1.4K | — |
| 2026-02-06 | Kraus Timothy R | Tax withheld | 41K | $30.40 |
| 2026-02-06 | Liedberg Douglas H | Grant | 81K | $30.40 |
| 2026-02-06 | Liedberg Douglas H | Option exercise | 1.2K | — |
| 2026-02-06 | Liedberg Douglas H | Tax withheld | 37K | $30.40 |
| 2026-02-06 | Foster Byron S. | Grant | 63K | $30.40 |
| 2026-02-06 | Foster Byron S. | Option exercise | 936 | — |
| 2026-02-06 | Foster Byron S. | Tax withheld | 28K | $30.40 |
| 2025-11-28 | McDonald R Bruce | Option exercise | 5.5K | — |
| 2025-11-28 | McDonald R Bruce | Tax withheld | 2.4K | $22.48 |
| 2025-11-25 | Price Craig C | Sell | 100 | $22.48 |
| 2025-11-25 | Price Craig C | Sell | 100 | $22.43 |
| 2025-11-25 | Price Craig C | Sell | 320 | $22.45 |
| 2025-11-25 | Price Craig C | Sell | 404 | $22.47 |
| 2025-11-25 | Price Craig C | Sell | 500 | $22.49 |
| 2025-11-25 | Price Craig C | Sell | 832 | $22.46 |
| 2025-11-25 | Price Craig C | Sell | 1.1K | $22.46 |
| 2025-11-25 | Price Craig C | Sell | 1.7K | $22.45 |
| 2025-11-25 | Price Craig C | Sell | 2.3K | $22.43 |
| 2025-11-25 | Price Craig C | Sell | 2.8K | $22.42 |
| 2025-11-25 | Price Craig C | Sell | 3.1K | $22.44 |
| 2025-11-25 | McDonald R Bruce | Option exercise | 1.2M | — |
| 2025-11-25 | McDonald R Bruce | Option exercise | 22K | — |
| 2025-11-25 | McDonald R Bruce | Tax withheld | 541K | $21.91 |
| 2025-08-13 | Kellett James D | Sell | 400 | $18.56 |
| 2025-08-13 | Kellett James D | Sell | 28 | $18.79 |
| 2025-08-13 | Kellett James D | Sell | 100 | $18.76 |
| 2025-08-13 | Kellett James D | Sell | 100 | $18.76 |
| 2025-08-13 | Kellett James D | Sell | 100 | $18.75 |
| 2025-08-13 | Kellett James D | Sell | 100 | $18.68 |
| 2025-08-13 | Kellett James D | Sell | 200 | $18.77 |
| 2025-08-13 | Kellett James D | Sell | 200 | $18.72 |
| 2025-08-13 | Kellett James D | Sell | 200 | $18.71 |
| 2025-08-13 | Kellett James D | Sell | 200 | $18.70 |
| 2025-08-13 | Kellett James D | Sell | 200 | $18.59 |
| 2025-08-13 | Kellett James D | Sell | 300 | $18.69 |
| 2025-08-13 | Kellett James D | Sell | 300 | $18.67 |
| 2025-08-13 | Kellett James D | Sell | 300 | $18.66 |
| 2025-08-13 | Kellett James D | Sell | 300 | $18.64 |
| 2025-08-13 | Kellett James D | Sell | 300 | $18.54 |
| 2025-08-13 | Kellett James D | Sell | 400 | $18.57 |
| 2025-08-13 | Kellett James D | Sell | 500 | $18.76 |
| 2025-08-13 | Kellett James D | Sell | 500 | $18.58 |
| 2025-08-13 | Kellett James D | Sell | 600 | $18.68 |
| 2025-08-13 | Kellett James D | Sell | 600 | $18.61 |
| 2025-08-13 | Kellett James D | Sell | 700 | $18.66 |
| 2025-08-13 | Kellett James D | Sell | 700 | $18.65 |
| 2025-08-13 | Kellett James D | Sell | 700 | $18.57 |
| 2025-08-13 | Kellett James D | Sell | 800 | $18.75 |
| 2025-08-13 | Kellett James D | Sell | 900 | $18.70 |
| 2025-08-13 | Kellett James D | Sell | 1.0K | $18.60 |
| 2025-08-13 | Kellett James D | Sell | 1.0K | $18.57 |
| 2025-07-22 | Pour Brian Keith | Tax withheld | 9.3K | $16.31 |
| 2025-07-22 | Pour Brian Keith | Option exercise | 20K | — |
| 2025-07-22 | Pour Brian Keith | Option exercise | 643 | — |
| 2025-02-15 | Valencia Antonio | Disposition | 9.0K | $16.09 |
| 2025-02-15 | Price Craig C | Option exercise | 2.6K | — |
| 2025-02-15 | Price Craig C | Option exercise | 239 | — |
| 2025-02-15 | Price Craig C | Tax withheld | 1.1K | $16.09 |
| 2025-02-15 | Liedberg Douglas H | Option exercise | 8.4K | — |
| 2025-02-15 | Liedberg Douglas H | Option exercise | 758 | — |
| 2025-02-15 | Liedberg Douglas H | Tax withheld | 4.1K | $16.09 |
| 2025-02-15 | Kraus Timothy R | Option exercise | 11K | — |
| 2025-02-15 | Kraus Timothy R | Option exercise | 994 | — |
| 2025-02-15 | Kraus Timothy R | Tax withheld | 5.2K | $16.09 |
| 2025-02-15 | Kellett James D | Option exercise | 2.0K | — |
| 2025-02-15 | Kellett James D | Option exercise | 181 | — |
| 2025-02-15 | Kellett James D | Tax withheld | 730 | $16.09 |
| 2025-02-15 | Foster Byron S. | Option exercise | 9.8K | — |
| 2025-02-15 | Foster Byron S. | Option exercise | 878 | — |
| 2025-02-15 | Foster Byron S. | Tax withheld | 4.8K | $16.09 |
| 2025-02-15 | Valencia Antonio | Option exercise | 8.3K | — |
| 2025-02-15 | Valencia Antonio | Option exercise | 747 | — |
| 2025-02-14 | Liedberg Douglas H | Option exercise | 11K | — |
| 2025-02-14 | WANDELL KEITH E | Option exercise | 12K | — |
| 2025-02-14 | WANDELL KEITH E | Option exercise | 425 | — |
| 2025-02-14 | OConnell Diarmuid B. | Option exercise | 12K | — |
| 2025-02-14 | OConnell Diarmuid B. | Option exercise | 425 | — |
| 2025-02-14 | McDonald R Bruce | Option exercise | 12K | — |
| 2025-02-14 | McDonald R Bruce | Option exercise | 425 | — |
| 2025-02-14 | McDonald R Bruce | Tax withheld | 5.6K | $16.09 |
| 2025-02-14 | Mack Michael J | Option exercise | 12K | — |
| 2025-02-14 | Mack Michael J | Option exercise | 425 | — |
| 2025-02-14 | LaFreniere Nora E. | Option exercise | 2.6K | — |
| 2025-02-14 | Karlin Bridget E | Option exercise | 12K | — |
| 2025-02-14 | Karlin Bridget E | Option exercise | 425 | — |
| 2025-02-14 | Hernandez Ernesto M | Option exercise | 12K | — |
| 2025-02-14 | Hernandez Ernesto M | Option exercise | 425 | — |
| 2025-02-14 | Hernandez Ernesto M | Tax withheld | 3.8K | $16.09 |
| 2025-02-14 | Valencia Antonio | Option exercise | 10K | — |
| 2025-02-14 | Valencia Antonio | Option exercise | 656 | — |
| 2025-02-14 | Valencia Antonio | Disposition | 11K | $16.09 |
| 2025-02-14 | Price Craig C | Option exercise | 3.8K | — |
| 2025-02-14 | Price Craig C | Option exercise | 236 | — |
| 2025-02-14 | Price Craig C | Tax withheld | 1.6K | $16.09 |
| 2025-02-14 | Liedberg Douglas H | Option exercise | 677 | — |
| 2025-02-14 | Liedberg Douglas H | Tax withheld | 5.0K | $16.09 |
| 2025-02-14 | Kraus Timothy R | Option exercise | 18K | — |
| 2025-02-14 | Kraus Timothy R | Option exercise | 1.1K | — |
| 2025-02-14 | Kraus Timothy R | Tax withheld | 8.2K | $16.09 |
| 2025-02-14 | Kellett James D | Option exercise | 2.4K | — |
| 2025-02-14 | Kellett James D | Option exercise | 148 | — |
| 2025-02-14 | Kellett James D | Tax withheld | 884 | $16.09 |
| 2025-02-14 | Foster Byron S. | Option exercise | 14K | — |
| 2025-02-14 | Foster Byron S. | Option exercise | 866 | — |
| 2025-02-14 | Foster Byron S. | Tax withheld | 6.6K | $16.09 |
| 2025-02-13 | Kraus Timothy R | Option exercise | 31K | — |
| 2025-02-13 | Kraus Timothy R | Option exercise | 1.1K | — |
| 2025-02-13 | Kraus Timothy R | Tax withheld | 14K | $15.80 |
| 2025-02-13 | Valencia Antonio | Disposition | 17K | $15.80 |
| 2025-02-13 | Foster Byron S. | Option exercise | 20K | — |
| 2025-02-13 | Foster Byron S. | Option exercise | 700 | — |
| 2025-02-13 | Foster Byron S. | Tax withheld | 9.5K | $15.80 |
| 2025-02-13 | Price Craig C | Option exercise | 6.3K | — |
| 2025-02-13 | Price Craig C | Option exercise | 215 | — |
| 2025-02-13 | Price Craig C | Tax withheld | 2.6K | $15.80 |
| 2025-02-13 | Liedberg Douglas H | Option exercise | 17K | — |
| 2025-02-13 | Liedberg Douglas H | Option exercise | 590 | — |
| 2025-02-13 | Liedberg Douglas H | Tax withheld | 7.9K | $15.80 |
| 2025-02-13 | Valencia Antonio | Option exercise | 16K | — |
| 2025-02-13 | Kellett James D | Option exercise | 3.5K | — |
| 2025-02-13 | Kellett James D | Option exercise | 117 | — |
| 2025-02-13 | Kellett James D | Tax withheld | 1.2K | $15.80 |
| 2025-02-13 | Valencia Antonio | Option exercise | 559 | — |
| 2025-02-11 | Valencia Antonio | Grant | 17K | $16.10 |
| 2025-02-11 | Price Craig C | Tax withheld | 2.4K | $16.10 |
| 2025-02-11 | Liedberg Douglas H | Grant | 17K | $16.10 |
| 2025-02-11 | Valencia Antonio | Disposition | 17K | $16.10 |
| 2025-02-11 | Foster Byron S. | Grant | 20K | $16.10 |
| 2025-02-11 | Foster Byron S. | Tax withheld | 9.3K | $16.10 |
| 2025-02-11 | Liedberg Douglas H | Tax withheld | 8.0K | $16.10 |
| 2025-02-11 | Kraus Timothy R | Grant | 23K | $16.10 |
| 2025-02-11 | Kraus Timothy R | Tax withheld | 10K | $16.10 |
| 2025-02-11 | Price Craig C | Grant | 5.4K | $16.10 |
| 2025-01-29 | OConnell Diarmuid B. | Other | 20K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT03675893 ↗ | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer Endometrial Cancer | PHASE2 | Recruiting | 2028-08-01 |
| NCT04986579 ↗ | Scalp Cooling in MBC Metastatic Breast Cancer, Chemotherapy-induced Alopecia | PHASE2 | Recruiting | 2028-06-01 |
| NCT04620187 ↗ | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Salivary Gland Cancer, HER2 Gene Mutation | PHASE2 | Recruiting | 2028-02-01 |
| NCT07397611 ↗ | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Renal Cell Carcinoma, Kidney Cancer | PHASE2 | Recruiting | 2028-01-31 |
| NCT03219450 ↗ | A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. Lymphocytic Leukemia | PHASE1 | Recruiting | 2027-07-31 |
| NCT07467772 ↗ | Ph 2 Elacestrant in ER Positive Uterine Sarcomas Uterine Sarcoma, Uterine Leiomyosarcoma | PHASE2 | Recruiting | 2027-07-01 |
| NCT06283251 ↗ | PediRISE Feasibility Pediatric Cancer, Financial Stress | NA | Recruiting | 2027-06-30 |
| NCT03152318 ↗ | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Malignant Glioma of Brain, Astrocytoma | PHASE1 | Active Not Recruiting | 2027-01-01 |
| NCT04434040 ↗ | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Breast Cancer, Triple Negative Breast Cancer | PHASE2 | Recruiting | 2026-12-30 |
| NCT04893109 ↗ | ATEMPT 2.0: Adjuvant T-DM1 vs TH Breast Cancer, HER2-positive Breast Cancer | PHASE2 | Recruiting | 2026-11-01 |
| NCT06202183 ↗ | Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial Colorectal Cancer, Metastatic Colon Cancer | NA | Recruiting | 2026-07-31 |
| NCT06468618 ↗ | Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients Stem Cell Transplant Complications, Sleep Disturbance | NA | Recruiting | 2026-06-01 |
| NCT02653755 ↗ | The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer Breast Cancer Radiation | PHASE2 | Active Not Recruiting | 2026-05-01 |
| NCT04569747 ↗ | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer HER2-positive Breast Cancer, Invasive Carcinoma of the Breast | PHASE2 | Active Not Recruiting | 2026-03-23 |
| NCT04846478 ↗ | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | PHASE1 | Active Not Recruiting | 2025-09-25 |
| NCT04717050 ↗ | Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity Breast Cancer, Coronary Artery Disease | NA | Active Not Recruiting | 2025-06-30 |
| NCT03709758 ↗ | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML Acute Myeloid Leukemia | PHASE1 | Active Not Recruiting | 2025-02-23 |
| NCT02873962 ↗ | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib Peritoneal Cancer, Ovarian Cancer | PHASE2 | Active Not Recruiting | 2025-02-01 |
| NCT03534323 ↗ | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Chronic Lymphocytic Leukemia, Richter Syndrome | PHASE1/PHASE2 | Active Not Recruiting | 2024-12-01 |
| NCT03054896 ↗ | A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome Richter Syndrome | PHASE2 | Active Not Recruiting | 2024-12-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (17)
- Ford Motor Company
- Stellantis N.V.
- Toyota Motor Corporation
- Renault-Nissan-Mitsubishi Alliance
- Tata Motors Ltd (including Jaguar Land Rover)
- General Motors Company
- Volkswagen AG
- Benteler Group
- Suzuki Motor Corporation
- Mercedes-Benz Group AG
- PACCAR Inc
- Traton SE
- AB Volvo
- Daimler Truck AB
- CNH Industrial N.V.
- Hinduja Group
- Oshkosh Corporation
Suppliers (0)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-12 | Exec/director changeExhibits | filing ↗ |
| 2026-06-11 | Material agreementExhibits | filing ↗ |
| 2026-06-11 | Reg FDExhibits | filing ↗ |
| 2026-05-15 | ResultsReg FDExhibits | filing ↗ |
| 2026-04-29 | ResultsReg FDExhibits | filing ↗ |
| 2026-04-23 | Shareholder vote | filing ↗ |
| 2026-03-25 | Reg FDExhibits | filing ↗ |
| 2026-02-18 | ResultsReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K/A | 2026-06-12 | 2026-02-11 | 0001193125-26-268470 ↗ |
| 8-K | 2026-06-11 | 2026-06-11 | 0001193125-26-266654 ↗ |
| 8-K | 2026-06-11 | 2026-06-10 | 0001193125-26-267630 ↗ |
| 10-Q | 2026-05-15 | 2026-03-31 | 0001437749-26-017296 ↗ |
| 8-K | 2026-05-15 | 2026-05-15 | 0001193125-26-226967 ↗ |
| 8-K | 2026-04-29 | 2026-04-29 | 0001193125-26-188909 ↗ |
| 8-K | 2026-04-23 | 2026-04-22 | 0001193125-26-173825 ↗ |
| 8-K | 2026-03-25 | 2026-03-25 | 0001193125-26-122764 ↗ |
| 10-K | 2026-02-27 | 2025-12-31 | 0001437749-26-006076 ↗ |
| 8-K | 2026-02-18 | 2026-02-18 | 0001193125-26-056030 ↗ |
| 8-K | 2026-02-12 | 2026-02-11 | 0000950142-26-000339 ↗ |
| 8-K | 2026-02-11 | 2026-02-10 | 0000950142-26-000333 ↗ |